November 05, 2015 | Bluebird Bio has released new interim results from its clinical trial of LentiGlobin gene therapy for beta-thalassemia and sickle cell disease, showing that it can wean patients off blood transfusions but that results are unexpectedly dependent on recipients' exact genotypes. TheStreet